Skip to content
    Real-World Studies

    Real-World Targeted Genomic Profiling in NSCLC

    Karlowatz et alFrontiers in Oncology

    Real-World Targeted Genomic Profiling in NSCLC
    A real-world retrospective analysis evaluated routine targeted genomic profiling in 528 patients with lung cancer from the North Swedish Health Care Region diagnosed between 2011 and 2021. Utilizing Archer VariantPlex 67-gene sequencing data linked to registry-derived clinical and demographic records, investigators evaluated tumor mutational profiles, positional architectures, subgroup enrichments, and overall survival associations, comparing findings internally and against an external reference cohort assembled from cBioPortal.
    Sequencing revealed marked mutational heterogeneity, identifying 1,415 somatic variants across 60 genes with an average of 2.68 mutations per tumor. While TP53 and KRAS formed a conserved genomic backbone across both the regional and reference cohorts, regional variations were pronounced: EGFR mutations were less frequent, whereas MET, APC, ATM, and CDKN2A were enriched in the North Swedish cohort. While hotspot architectures were broadly preserved between cohorts, MET exhibited the most prominent positional divergence.
    Distinct clinical and demographic correlations emerged across genomic subsets. EGFR alterations delineated a coherent clinical phenotype, showing significant enrichment among female patients, never-smokers, younger individuals, and those presenting with earlier-stage disease. Conversely, mutations in KRAS, STK11, and TP53 correlated with smoking exposure. Prognostically, EGFR was identified as the strongest favorable marker, though disease stage substantially influenced the interpretation of survival differences across subgroups. These findings demonstrate that routine molecular profiling yields valuable prognostic and phenotypic insight beyond solitary driver detection when interpreted alongside disease stage, smoking history, demographic variables, and regional genomic baseline patterns.

    Key Takeaways

    • Analysis of 528 lung cancer tumors identified 1,415 somatic variants across 60 genes—averaging 2.68 mutations per tumor—with conserved TP53 and KRAS mutations across cohorts, lower EGFR frequency, and regional enrichment of MET, APC, ATM, and CDKN2A relative to an external cBioPortal reference cohort.
    • EGFR mutations represented the strongest favorable prognostic marker and were significantly enriched in females, never-smokers, younger individuals, and earlier-stage disease, whereas KRAS, STK11, and TP53 mutations were associated with a positive smoking history.
    Read the original sourceFrontiers in Oncology